Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 340 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Essential Amino Acid+ Clear all
Active, not recruiting Phase 1 Interventional

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

NCT04800692
View directory record Official record
Conditions
Claudication, Intermittent, Peripheral Artery Disease, Peripheral Vascular Diseases
Interventions
Tetrahydrobiopterin 10 mg/kg, Tetrahydrobiopterin 20 mg/kg, L-Ascorbate, L-Arginine
Drug
Lead sponsor
Louis Messina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma

NCT00280683
View directory record Official record
Conditions
Asthma
Interventions
L-arginine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 1, 2026, 1:33 AM EDT
Not listed Not applicable Interventional

Nutritional Stimulation of Muscle Protein Synthesis and Metabolic Rate After Bariatric Surgery

NCT04751916
View directory record Official record
Conditions
Weight Loss
Interventions
Essential Amino Acid Protein Supplement, Beneprotein®
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pea vs Whey Protein Supplementation With Resistance Training on Young Adults' Strength, Body Composition, and Metabolic Parameters

NCT07420933
View directory record Official record
Conditions
Healthy Subjects
Interventions
Protein Isolate, Progressive Resistance Exercise Training (PRE)
Dietary Supplement · Behavioral
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 30 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Not applicable Interventional Results available

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS

NCT03717935
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions
Essential Amino Acid (EAA) Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 1, 2026, 1:33 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis

NCT00014768
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
glucose, insulin, leucine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 1, 2026, 1:33 AM EDT
Withdrawn Phase 3 Interventional

Optimal Treatment for Kidney Disease in HIV Infected Adults

NCT00089518
View directory record Official record
Conditions
HIV Infections, Kidney Disease
Interventions
Valsartan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Indianapolis, Indiana • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

NCT01681576
View directory record Official record
Conditions
Salt-sensitive Hypertension
Interventions
Valsartan, LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Results available

Phase Ib of L-NMMA and Pembrolizumab

NCT03236935
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma Bladder, DNA Repair-Deficiency Disorders
Interventions
L-NMMA, Pembrolizumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

NCT00327587
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan + amlodipine, Valsartan + HCTZ, Amlodipine + HCTZ, Valsartan + amlodipine + HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 1, 2026, 1:33 AM EDT
Not yet recruiting Early Phase 1 Interventional

Sarcopenia in Chronic Kidney Disease (CKD) Patients

NCT07437053
View directory record Official record
Conditions
Chronic Kidney Disease, Sarcopenia
Interventions
Valine, EEA
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
45 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Practical Anemia Bundle for SusTained Blood Recovery

NCT05167734
View directory record Official record
Conditions
Anemia, Critical Illness
Interventions
Iron Dextran, Erythropoietin (EPO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Pegasys® in Patients With Myeloproliferative Diseases

NCT00452023
View directory record Official record
Conditions
Myeloproliferative Disorders
Interventions
IFN-alpha2a
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Serotonin on Changing Brain Chemistry

NCT01208324
View directory record Official record
Conditions
Menopause
Interventions
estrogen patch, Amino acids, Placebo Patch, Placebo pills
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
48 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 4 Interventional

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

NCT00168779
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg / hydrochlorothiazide 25 mg, valsartan 160 mg / hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
113
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

NCT03180593
View directory record Official record
Conditions
Hypertension Complicated, Hypertrophy, Left Ventricular, Blood Pressure
Interventions
Valsartan 80 mg
Drug
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 1, 2026, 1:33 AM EDT
Recruiting Not applicable Interventional

Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19

NCT04858412
View directory record Official record
Conditions
Alcoholic Liver Disease, COVID 19 Pneumonia
Interventions
β-hydroxy β-methyl butyrate (HMB) enriched amino acid, Balanced amino acid
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis

NCT00006367
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders
Interventions
filgrastim, busulfan, cytarabine, idarubicin, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
7
States / cities
Anchorage, Alaska • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
87
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 1, 2026, 1:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses

NCT07121010
View directory record Official record
Conditions
Cardiometabolic Health
Interventions
Animal-Based Protein Smoothie, Plant-Based Protein Smoothie, Plant-Based Protein Smoothie with Leucine
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma Triglyceride Extraction by The Muscle

NCT01860911
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Insulin, NG-monomethyl-L-arginine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 1, 2026, 1:33 AM EDT
Terminated Phase 4 Interventional Results available

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

NCT01129557
View directory record Official record
Conditions
Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 1, 2026, 1:33 AM EDT
Terminated Phase 1 Interventional

Prospective L-arginine Study

NCT01485757
View directory record Official record
Conditions
Heart Transplant
Interventions
L-arginine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
8 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 1, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

NCT02874794
View directory record Official record
Conditions
Heart Failure and Reduced Ejection Fraction
Interventions
LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
81
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 1, 2026, 1:33 AM EDT